OPTIMISING MULTIDISCIPLINARY CARE FOR MELANOMA PATIENTS IN 2024



New paradigms: New standards of care

Networking dinner

Thursday 18 April 2024; 6:30pm – 9:30pm

Graduate House, University of Melbourne 220 Leicester St, Carlton VIC 3053

You are invited to join your colleagues for a three-course dinner. Foster existing connections and collaborations and expand your network by creating new connections with delegates from a wide range of melanoma-related disciplines.

Workshop program

Friday 19 April 2024; 8:30am – 3:30pm

Woodward Conference Centre, University of Melbourne Law Building, 10th Floor, 106/185 Pelham St, Carlton VIC 3053

Aims: Provide an overview of the significant transformations that have occurred in the melanoma field over the past 5 years, spanning adjuvant/neo strategies, translational research, and the integration of combination therapies, while also focusing on a better understanding of the mechanisms of treatment response

Learning objectives:

- Summarise key advancements in adjuvant/neo strategies in the melanoma field over the last 5 years.
- Outline developments in translational research of Melanoma Neoadjuvant therapies.
- Explore the integration of combination therapies and their impact on melanoma treatment progress.
- Outline developments in translational research within the melanoma domain during the specified timeframe.

Time	Торіс	Speaker
8.30am	Arrival and registration	
8:40am	Welcome & Introduction	A/Prof David Gyorki
8:45am	Sponsor presentation - MSD	Dr Alisha Jung
Session 1: Bridging the gap - Bringing science into the clinic		Chair: A/Prof Shahneen Sandhu
8:50am	Utilising the microbiome to improve outcomes for patients with stage III melanoma	Dr Miles Andrews
9.05am	Using mouse models to understand the role of tumour draining lymph nodes in melanoma	Prof Thomas Gebhardt
9.20am	Understand immune response in melanoma using preclinical models	ТВС
9.35am	Adjuvant therapy for stage II and III melanoma. How do we decide who to give it to?	A/Prof Oliver Klein
9.50am	Novel biomarkers to inform clinical decision making in stage III melanoma	Dr Charlotte Ariyan
10.20am	Panel discussion Panellists: A/Prof Andreas Behren, Prof Thomas Gebhardt, Dr Charlotte Ariyan, Dr Miles Andrews, A/Prof Oliver Klein	Moderator: A/Prof Shahneen Sandhu
10.40am	Morning tea	
	Morning tea Adjuvant & neoadjuvant therapies	Chair: A/Prof David Gyorki
Session 2:	Adjuvant & neoadjuvant therapies Opportunities and barriers for Melanoma Neoadjuvant therapies	
Session 2:	Adjuvant & neoadjuvant therapies Opportunities and barriers for Melanoma Neoadjuvant therapies Multidisciplinary approach: - Neoadjuvant therapy – paradigm shift and what does the	
Session 2:	 Adjuvant & neoadjuvant therapies Opportunities and barriers for Melanoma Neoadjuvant therapies Multidisciplinary approach: Neoadjuvant therapy – paradigm shift and what does the future hold – A/Prof Shahneen Sandhu The evolution of the role of surgery for patients with resectable macroscopic lymphadenopathy – A/Prof Alex 	
Session 2:	 Adjuvant & neoadjuvant therapies Opportunities and barriers for Melanoma Neoadjuvant therapies Multidisciplinary approach: Neoadjuvant therapy – paradigm shift and what does the future hold – A/Prof Shahneen Sandhu The evolution of the role of surgery for patients with resectable macroscopic lymphadenopathy – A/Prof Alex van Akkooi How to approach a lymphadenectomy specimen after 	
Session 2: 11.00am	 Adjuvant & neoadjuvant therapies Opportunities and barriers for Melanoma Neoadjuvant therapies Multidisciplinary approach: Neoadjuvant therapy – paradigm shift and what does the future hold – A/Prof Shahneen Sandhu The evolution of the role of surgery for patients with resectable macroscopic lymphadenopathy – A/Prof Alex van Akkooi How to approach a lymphadenectomy specimen after neoadjuvant therapy – Dr Louise Jackett 	Gyorki
Session 2: 11.00am	 Adjuvant & neoadjuvant therapies Opportunities and barriers for Melanoma Neoadjuvant therapies Multidisciplinary approach: Neoadjuvant therapy – paradigm shift and what does the future hold – A/Prof Shahneen Sandhu The evolution of the role of surgery for patients with resectable macroscopic lymphadenopathy – A/Prof Alex van Akkooi How to approach a lymphadenectomy specimen after neoadjuvant therapy – Dr Louise Jackett Disseminating information for surgical community Case discussion and panel A/Prof Shahneen Sandhu, A/Prof Alex van Akkooi, Dr Louise Jackett, A/Prof Sydney Ch'ng, Dr Charlotte Ariyan, Mr Peter Gourlay, Dr 	Gyorki A/Prof Sydney Ch'ng Moderator: A/Prof
Session 2: 11.00am 11.45am 12.00pm	 Adjuvant & neoadjuvant therapies Opportunities and barriers for Melanoma Neoadjuvant therapies Multidisciplinary approach: Neoadjuvant therapy – paradigm shift and what does the future hold – A/Prof Shahneen Sandhu The evolution of the role of surgery for patients with resectable macroscopic lymphadenopathy – A/Prof Alex van Akkooi How to approach a lymphadenectomy specimen after neoadjuvant therapy – Dr Louise Jackett Disseminating information for surgical community Case discussion and panel A/Prof Shahneen Sandhu, A/Prof Alex van Akkooi, Dr Louise Jackett, A/Prof Sydney Ch'ng, Dr Charlotte Ariyan, Mr Peter Gourlay, Dr Jessica Duarte Book Launch: 'Atlas of Keystone Reconstructive Technique in the 	Gyorki A/Prof Sydney Ch'ng Moderator: A/Prof David Gyorki

Session 3: Unresectable Stage III Melanoma		Chair: A/Prof Craig Underhill
1.40pm	Combining immunotherapy with regional therapies to improve efficacy – what treatments for which patients?	Dr Charlotte Ariyan
2.00pm	Debate: How do we decide on first line treatment for unresectable locoregionally advanced disease? Drugs first: Dr Lavinia Spain Regional therapies first: Dr Hayden Snow Radiation first: Dr Margaret Chua	Moderator: A/Prof Craig Underhill
2.30pm	The next paradigm shift – what will melanoma treatment look like over the next decade?	Prof Mark Shackleton
2.50pm	Case discussion and panel Dr Charlotte Ariyan, Ms Alethea Lobo, Ms Tamara Dawson, Dr Lavinia Spain, Dr Hayden Snow, Dr Margaret Chua, Prof Mark Shackleton	Moderator: A/Prof Craig Underhill
3.30pm	Conclusion & closing remarks	A/Prof David Gyorki

Sponsor





VCCC Alliance members







Western Health









murdoch children's
research institute

Supported by



